Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines

Stanislav Sotirov,Ivan Dimitrov

DOI: https://doi.org/10.3390/ijms25094934

IF: 5.6

2024-05-01

International Journal of Molecular Sciences

Abstract:Peptide antigens derived from tumors have been observed to elicit protective immune responses, categorized as either tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). Subunit cancer vaccines incorporating these antigens have shown promise in inducing protective immune responses, leading to cancer prevention or eradication. Over recent years, peptide-based cancer vaccines have gained popularity as a treatment modality and are often combined with other forms of cancer therapy. Several clinical trials have explored the safety and efficacy of peptide-based cancer vaccines, with promising outcomes. Advancements in techniques such as whole-exome sequencing, next-generation sequencing, and in silico methods have facilitated the identification of antigens, making it increasingly feasible. Furthermore, the development of novel delivery methods and a deeper understanding of tumor immune evasion mechanisms have heightened the interest in these vaccines among researchers. This article provides an overview of novel insights regarding advancements in the field of peptide-based vaccines as a promising therapeutic avenue for cancer treatment. It summarizes existing computational methods for tumor neoantigen prediction, ongoing clinical trials involving peptide-based cancer vaccines, and recent studies on human vaccination experiments.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the possibility of tumor - derived antigenic peptides as potential cancer vaccines. Specifically, the paper focuses on the following aspects:

1. **Selection and Identification of Tumor Antigens**: The paper discusses how to select and identify tumor - associated antigens (TAAs) and tumor - specific antigens (TSAs), which can be used to develop cancer vaccines. The author emphasizes that the ideal antigen should be expressed only by cancer cells and be highly immunogenic.

2. **Antigen Processing and Presentation Mechanisms**: The paper details how antigens are processed, presented to immune cells, and finally recognized by T cells. This includes proteolysis of antigens, binding to major histocompatibility complex (MHC) molecules, and the expression of p - MHC complexes on the cell surface.

3. **New Antigen Prediction Methods**: The paper reviews current computational methods for predicting tumor neo - antigens, such as whole - exome sequencing (WES), next - generation sequencing (NGS), and machine - learning algorithms. These methods are helpful for screening out potentially immunogenic neo - antigens from a large number of mutations.

4. **Progress in Clinical Trials**: The paper summarizes the ongoing clinical trials evaluating the safety and efficacy of peptide - based cancer vaccines. These trials involve multiple cancer types, including melanoma, prostate cancer, lung cancer, etc.

5. **Human Vaccination Experiments**: The paper also reviews some verified human cancer peptide vaccination experiments, which provide valuable data demonstrating the potential of peptide - based cancer vaccines in practical applications.

Overall, this paper aims to comprehensively overview the research progress of peptide - based cancer vaccines, especially for tumor - derived antigenic peptides, in the hope of providing new ideas and methods for future cancer treatment.